Bashas’ launches ‘Eat Smart’ program
CHANDLER, Ariz. A supermarket chain in Arizona has launched a new program to encourage healthy eating habits.
Bashas’ Supermarkets announced on Friday the launch of its “Eat Smart” program, which it describes as a comprehensive nutrition program for customers including nutrition shelf tags that identify the health benefits of foods, a free “Eat Smart” newsletter, shopping tours and end-cap displays that feature healthy products.
The chain will also offer a “Healthy Kitchen Makeover” contest in which adults can submit photos of their refrigerators, freezers or kitchen pantries, along with an essay of 200 words or fewer explaining why their kitchens need makeovers. Three winners will receive a $500 gift card and consultation with a dietician.
Publix to open 1,000th store Feb. 5
LAKELAND, Fla. Publix will open the doors to store No. 1,000 on Feb. 5, the grocer announced Thursday. The latest addition to Publix, which will stand at 54,000 sq. ft., will include a pharmacy, bakery, deli and floral and fresh seafood departments.
“We are proud of our 79-year history, rich in providing superior customer service and delivering a high-quality selection of foods, products and services,” stated Publix president Todd Jones.
Opening day festivities will begin with a performance by the St. John’s Academy of the Arts choral group. To commemorate the milestone, Publix will grant eight local area schools $1,000 each to use toward the purchase of school supplies.
According to the company, the Florida Historical Society will be on-hand to recognize and document Publix’ milestone.
Eli Lilly agrees to settlement over alleged mispromotion of Zyprexa
WASHINGTON Drug maker Eli Lilly & Co. has agreed to pay $1.415 billion to resolve allegations that it promoted the antipsychotic drug Zyprexa for unapproved uses.
The Department of Justice announced Thursday that the Indianapolis-based company would pay a $515 million criminal fine (the largest ever in a healthcare case and the largest criminal fine ever imposed on an individual corporation) and up to $800 million in a civil settlement with the federal government and the states. It will also forfeit assets of $100 million.
The settlement will resolve criminal and civil allegations that Lilly promoted Zyprexa (olanzapine) for uses not approved by the Food and Drug Administration, including treatment of dementia in elderly people.
In a plea agreement, the company has admitted its guilt to a misdemeanor charge. It also signed a civil settlement to resolve claims that by marketing the drug for off-label uses, it caused the submission of false payment claims to federal health insurance plans such as Medicaid, TRICARE and the Federal Employee Health Benefits Program.